- Home
- FTHA vs NRXP Comparison
FTHA vs NRXP Comparison
Compare FTHA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHA | NRXP |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.8M | 151.1M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FTHA | NRXP |
|---|---|---|
| Price | $10.03 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.75 |
| AVG Volume (30 Days) | 47.9K | ★ 1.3M |
| Earning Date | N/A | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,281.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $1.65 |
| 52 Week High | $10.05 | $5.06 |
Technical Indicators
Market Signals| Indicator | FTHA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 74.37 | 43.77 |
| Support Level | $9.90 | $1.68 |
| Resistance Level | N/A | $2.49 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 92.31 | 42.47 |
Price Performance
Historical ComparisonAbout FTHA Forefront Tech Holdings Acquisition Corp Class A Ordinary Shares
Forefront Tech Holdings Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.